Hidradenitis Suppurativa Clinical Trials Lack People of Color

By Rob Dillard - January 25, 2023

A recent study shows that there is a notable lack of ethnic minority representation in hidradenitis suppurativa (HS) clinical trials. The findings were reported in Archives of Dermatological Research.

To conduct this study, researchers queried the US National Library of Medicine clinical trials database for HS clinical trials. After excluding trials that did not provide ethnic or racial data, the researchers analyzed a total of 57 HS trials comprised of 2,530 patients.

According to the results, white patients made up the majority of the study population at 76.1%, followed by Blacks at 13.7%, Hispanics at 7.2%, Asians at 2.6%, American Indians or Alaska Natives at 1.3%, and Native Hawaiians or Other Pacific Islanders at 0.4%.

Our results establish a significant lack of minority ethnoracial representation in HS clinical trials. Since HS prevalence is highest among Blacks or African Americans, it is imperative that future clinical trials are conducted with a larger proportion of this population,” the researchers concluded. However, citing a possible study limitation, they added that “clinical trials that did not report racial or ethnic information were conducted in countries with predominantly White populations, which likely skewed the results of this study and caused underreporting of these patients.”

Latest News

March 24, 2023